Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
2005 Standout
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
2007 StandoutNobel
The Brazilian health system: history, advances, and challenges
2011 Standout
Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction.
1988
Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis.
1985
The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality
1986
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
2004
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
Blood Pressure Variability Causes Spurious Identification of Hypertension in Clinical Studies: A Computer Simulation Study
2007
Prevalence, awareness and treatment of hypertension in Finland during 1982–2007
2009
Allopurinol hypersensitivity: investigating the cause and minimizing the risk
2015
Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
1990 Standout
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
1998 Standout
Global burden of hypertension: analysis of worldwide data
2005 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout
A Systematic Review of the Effects of Home Blood Pressure Monitoring on Medication Adherence
2006
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
2005 Standout
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias
2007
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
2004 Standout
Porphyrias
2010 Standout
Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries
2013 Standout
Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial
2009
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
2010
Global risk of cardiovascular disease
2003
Gout
2009 Standout
Relation between adverse events associated with allopurinol and renal function in patients with gout
2001
Chronic kidney disease
2011 Standout
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
2008
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Prevention of Heart Failure
2008
Gout
2016 Standout
Atenolol in hypertension: is it a wise choice?
2004
Tensions in public health policy: patient engagement, evidence-based public health and health inequalities
2005
A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: Secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial
2006
Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy
2013 Standout
Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy
2009
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
1995 Standout
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
2012
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
2004 Standout
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
2005 Standout
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis
2005
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)
2004
Rationale and design of the Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): A factorial, cluster-randomized trial of 2 practical cardiovascular disease prevention strategies developed for rural Andhra Pradesh, India
2009
Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke
2010
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012
2013
Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes
2006 Standout
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
2005 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
2006 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects
1996
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
A Computerised Guidance Tree (Decision Aid) for Hypertension, Based on Decision Analysis: Development and Preliminary Evaluation
2005
Global Disparities of Hypertension Prevalence and Control
2016 Standout
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
Decision aids for people facing health treatment or screening decisions
2017 Standout
Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial.
2009
Statins for the primary prevention of cardiovascular disease
2013
Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout
2014
Treatment-Induced Blood Pressure Reduction and the Risk of Myocardial Infarction
1989
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths
2007 Standout
Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa
2005
Nebivolol
2006
Blood pressure, stroke, and coronary heart disease
1990 Standout
Gout
2021 Standout
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology
2004
Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials
2008
Applicability to primary care of national clinical guidelines on blood pressure lowering for people with stroke: cross sectional study
2006
Severe allopurinol toxicity
1984
Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus
2005
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
2005
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006 Standout
Inclusion of Stroke in Cardiovascular Risk Prediction Instruments
2012
Allopurinol Hypersensitivity Syndrome: A Review
1993
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
As redes de atenção à saúde
2010 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
2008 Standout
Works of GT McInnes being referenced
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol
2001
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV
2004
Acute adverse reactions attributed to allopurinol in hospitalised patients.
1981
Delivery of care for hypertension.
1995
Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients
2001
Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease?
1988
Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double‐blind randomised study.
1995
Hepatic enzyme induction and leucocyte delta‐aminolaevulinic acid synthase activity: studies with carbamazepine.
1983